I’ve waited 5 years to write these words: On 31 August 2026, the first two participants each received a dose of PVX-001, our broadly-protective COVID-19 vaccine candidate designed to protect against future variants of SARS-CoV-2 that may emerge, in a first-in-human Phase I clinical trial in Melbourne, Australia (ACTRN12626000891325).
This trial, which will enroll a total of 36 healthy adult volunteers, is intended to assess the safety and tolerability of the vaccine candidate, while also providing early data on the magnitude and breadth of the immune response it elicits against multiple variants of SARS-CoV-2. As of 6 October 2026, we have enrolled and dosed 14 participants meeting our screening criteria, with no serious adverse events (SAEs) reported. Participant follow-up and safety monitoring are ongoing.
